Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

228
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
228
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

379
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
379
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

319
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
319
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

353
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
353
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

206
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
206
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.6K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Compounds for Inhibiting Viral Replication and Treating and/or Preventing Coronavirus Infections.

ACS medicinal chemistry letters·2026
Same author

Novel Compounds as SARS-CoV‑2 Main Protease Inhibitors for Treating Viral Infections, in particular, Coronavirus Infections.

ACS medicinal chemistry letters·2026
Same author

Novel 5,6-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.

ACS medicinal chemistry letters·2026
Same author

Novel Tetrahydroquinazoline Derivatives for Treating HIV Infection or AIDS or AIDS Related Complex.

ACS medicinal chemistry letters·2026
Same author

Novel Bridged Tricyclic Carbamoylpyridone Compounds as HIV Integrase Inhibitors for Treating HIV Infection.

ACS medicinal chemistry letters·2026
Same author

Novel Compounds as CDK4 Inhibitors for Treating Breast Cancer.

ACS medicinal chemistry letters·2026

Related Experiment Video

Updated: Jul 30, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K

Novel AHR Agonists for Treating Psoriasis.

Ram W Sabnis1

  • 1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.

ACS Medicinal Chemistry Letters
|May 17, 2023
PubMed
Summary

New aryl hydrocarbon receptor agonists offer potential treatments for immune-mediated diseases like psoriasis. These compounds and their pharmaceutical compositions represent a novel therapeutic approach for managing inflammatory conditions.

Area of Science:

  • Pharmacology
  • Immunology
  • Medicinal Chemistry

Background:

  • Aryl hydrocarbon receptor (AhR) agonists are investigated for their immunomodulatory properties.
  • Immune-mediated diseases, such as psoriasis, represent a significant unmet medical need.
  • Developing novel therapeutic agents targeting specific molecular pathways is crucial.

Discussion:

  • This work introduces novel aryl hydrocarbon receptor (AhR) agonists.
  • The pharmaceutical compositions comprise these novel agonists.
  • The described compounds are utilized in treating immune-mediated diseases, with a specific focus on psoriasis.

Key Insights:

  • Novel AhR agonists have been synthesized and characterized.
  • These agonists demonstrate potential in the therapeutic landscape of immune-mediated diseases.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.2K

Related Experiment Videos

Last Updated: Jul 30, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.2K
  • The study outlines processes for the preparation of these promising compounds.

    • Outlook:

    • Further research into the efficacy and safety of these AhR agonists is warranted.
    • These compounds may offer a new class of drugs for psoriasis and other immune disorders.
    • The development of efficient synthetic routes facilitates potential clinical translation.